Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in EGFRm Advanced NSCLC: The COCOON Global RCT
Panelists discuss how proactive dermatologic management using the protocol from the COCOON randomized, controlled trial (RCT) can significantly reduce grade 2 or higher skin-related adverse events from 73% to 41% in EGFR-mutated non–small cell lung cancer patients treated with amivantamab, emphasizing the shift from reactive to preventive care strategies to improve quality of life and treatment adherence.
EP. 1: Overview of NSCLC and Dermatologic Management
September 17th 2025Panelists discuss how patients with EGFR-mutated non–small cell lung cancer develop dermatologic adverse events with amivantamab treatment, presenting as papules, pustules, and paronychia that significantly impact quality of life.
EP. 2: Provider Perspectives on Managing EGFRm NSCLC
September 17th 2025Panelists discuss how dermatologic adverse events with EGFR inhibitors are more severe than previously seen with third-generation tyrosine kinase inhibitors, requiring reactive management strategies including topical steroids, antibiotics, and dermatologic consultations that are often difficult to obtain.
